By Jessica Skarzynski
The Food and Drug Administration has approved Zejula for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer that have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous … Read more
By Wayne Kuznar
The case for the combination of olaparib (Lynparza) and durvalumab (Imfinzi) in patients with metastatic breast cancer and relapsed ovarian cancer with germline BRCA mutations was strengthened based on the updated results from the phase I/II MEDIOLA, … Read more
A laboratory study published in Clinical Cancer Research offers a new hypothesis about how ovarian cancer forms and suggests how it might be prevented.
The study is the first to show that the natural stiffening of the ovaries called fibrosis … Read more
We would love to hear from the Clearity Community – patients, caregivers, and loved ones – about your experiences on how you have been affected by ovarian cancer. Sharing your story is a way to promote awareness, connect with people … Read more
With so much information at your fingertips, we understand how difficult it can be to find trustworthy, lay friendly sources that are relevant to you and your specific ovarian cancer journey. The Clearity Foundation exists to help women find credible … Read more
By Charles Bankhead
Anti-folate fails phase III test, but key biomarker measurement may have been faulty.
An antibody-drug conjugate (ADC) targeting folate-receptor expression failed to improve progression-free survival (PFS) versus chemotherapy in patients with recurrent platinum-resistant ovarian cancer, according to … Read more
By Pam Harrison
Targeted drug provokes good response in chemoresistant, low-grade serous ovarian or peritoneal cancer.
Trametinib (Mekinist) treatment was associated with better outcomes in women with recurrent or progressive low-grade serous ovarian or peritoneal cancer versus treatment with standard-of-care … Read more
By Ed Susman
PRIMA and VELIA trial findings advance niraparib and veliparib to the therapeutic front lines.
Patients with newly diagnosed advanced ovarian cancer who responded to first-line chemotherapy, then were treated with niraparib (Zejula), had a significantly reduced risk … Read more
By Charles Bankhead
Olaparib-bevacizumab maintenance boosts PARP inhibitor benefits beyond BRCA-mutated subgroup.
Dual maintenance therapy with olaparib (Lynparza) and bevacizumab (Avastin) significantly improved progression-free survival (PFS) in women with newly diagnosed advanced ovarian cancer, as compared with single-agent bevacizumab, a … Read more
By Dave Levitan
The combination of niraparib and bevacizumab significantly improved progression-free survival compared with niraparib alone in a phase II study of patients with platinum-sensitive recurrent ovarian cancer. The chemotherapy-free regimen will now be tested in a phase III … Read more
Although the number of women being diagnosed and dying of ovarian cancer is declining, recurrence, drug resistance, and mortality remains high for women with high-grade serous ovarian carcinoma, the most common form of epithelial ovarian cancer.
A new study in … Read more
By Thomas J. Pier, MSW, LCSW, OSW-C, CMF, and Marina Baroff, MPH, MA, FACHE
What if every woman with ovarian cancer had help setting a clear direction through the uncertain landscape of the diagnosis? Imagine these women having access to … Read more
By Peter MacCallum
An international study led by Peter Mac has revealed the origin of mucinous ovarian cancer (MOC) confirming, unlike other types of ovarian cancer, this rare cancer is not seeded from elsewhere in the body.
The research provides … Read more
By Dr. Laura Shawver, Founder of The Clearity Foundation
Whenever I talk with someone who just received an ovarian cancer diagnosis, it brings back the feelings that I had when I heard the words, “you have ovarian cancer.” I can … Read more
By Dave Levitan
The combination of a poly (ADP-ribose) polymerase (PARP) inhibitor and immune checkpoint inhibition with tislelizumab was well tolerated and showed promising anti-tumor activity in a phase I trial of patients with multiple solid tumor types, according to … Read more
Researchers from Queen’s University Belfast have developed a test that may be able to detect ovarian cancer up to two years earlier than current approaches.
The researchers discovered that the presence of four proteins together, known as a biomarker panel, … Read more
This article discusses the anxiety that often surrounds a cancer diagnosis and the importance of seeking professional help. Steps Through OC offers free, professional ovarian cancer counseling for women, families and caregivers coping with ovarian cancer. Our goal is to … Read more
By John Lauerman
AstraZeneca Plc’s Lynparza got a boost from results of a study that may widen the drug’s use among patients with advanced ovarian cancer.
Ovarian tumor growth slowed in patients who got Lynparza in addition to a … Read more
By Michael J. Birrer, MD, PhD
There will be 22,530 new cases of ovarian cancer in the United States this year.
Although tumors often present at an advanced stage, it remains one of the most chemosensitive epithelial cancers, with a … Read more
By Kristen Monaco
Researchers advocate for increased hormone therapy for high-risk women.
Bone health suffered in women with a BRCA mutation who underwent preventive oophorectomy, Canadian researchers reported.
Premenopausal women with the BRCA1 or BRCA2 mutation experienced a significant decline … Read more
